HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Margaret C Frame Selected Research

Focal Adhesion Protein-Tyrosine Kinases

7/2022Editor's Note: Identification of Src-Specific Phosphorylation Site on Focal Adhesion Kinase: Dissection of the Role of Src SH2 and Catalytic Functions and Their Consequences for Tumor Cell Behavior.
1/2021FAK regulates IL-33 expression by controlling chromatin accessibility at c-Jun motifs.
1/2018Structure-Based Design, Synthesis, and Characterization of the First Irreversible Inhibitor of Focal Adhesion Kinase.
12/2017IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks.
10/2017Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth.
4/2016FAK goes nuclear to control antitumor immunity-a new target in cancer immuno-therapy.
9/2015p70S6K is regulated by focal adhesion kinase and is required for Src-selective autophagy.
12/2014Eps8 controls Src- and FAK-dependent phenotypes in squamous carcinoma cells.
7/2012The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells.
2/2012Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Margaret C Frame Research Topics

Disease

48Neoplasms (Cancer)
07/2022 - 06/2002
8Squamous Cell Carcinoma (Epidermoid Carcinoma)
12/2017 - 02/2009
8Colonic Neoplasms (Colon Cancer)
09/2008 - 08/2002
7Neoplasm Metastasis (Metastasis)
12/2017 - 01/2005
5Carcinogenesis
05/2011 - 02/2009
3Breast Neoplasms (Breast Cancer)
01/2016 - 01/2012
3Carcinoma (Carcinomatosis)
12/2014 - 02/2005
2Pancreatic Neoplasms (Pancreatic Cancer)
01/2021 - 08/2013
2Glioblastoma (Glioblastoma Multiforme)
01/2021 - 06/2011
2Cicatrix (Scar)
01/2013 - 01/2006
2autosomal recessive 1 Spinocerebellar ataxia
01/2006 - 12/2004
1Brain Neoplasms (Brain Tumor)
01/2021
1Inflammation (Inflammations)
01/2021
1Melanoma (Melanoma, Malignant)
04/2015
1Astrocytoma (Pilocytic Astrocytoma)
06/2011
1Adenocarcinoma
07/2010
1Disease Progression
07/2010
1Wounds and Injuries (Trauma)
06/2010
1Papilloma (Papillomatosis)
02/2009
1Gliosis
07/2007
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
05/2007

Drug/Important Bio-Agent (IBA)

21Focal Adhesion Protein-Tyrosine KinasesIBA
07/2022 - 12/2004
12Proteins (Proteins, Gene)FDA Link
01/2020 - 12/2004
10Phosphotransferases (Kinase)IBA
11/2021 - 06/2002
9IntegrinsIBA
01/2013 - 08/2002
8src-Family KinasesIBA
01/2016 - 06/2004
6Cadherins (E-Cadherin)IBA
01/2013 - 08/2002
4CytokinesIBA
01/2021 - 08/2010
4Pharmaceutical PreparationsIBA
08/2013 - 10/2004
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
07/2014 - 10/2004
3Dasatinib (BMS 354825)FDA Link
08/2013 - 12/2006
3Biomarkers (Surrogate Marker)IBA
08/2010 - 12/2006
2Interleukin-33IBA
01/2021 - 12/2017
2ChemokinesIBA
04/2016 - 09/2015
2Actin-Related Protein 2-3 Complex (Arp2 3 Complex)IBA
01/2013 - 01/2006
2Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
08/2012 - 01/2011
2Phosphoric Monoester Hydrolases (Phosphatases)IBA
06/2011 - 06/2007
2CalpainIBA
05/2011 - 12/2002
2Phosphatidylinositols (Phosphatidylinositol)IBA
06/2007 - 05/2007
2LipidsIBA
06/2007 - 05/2007
1Anti-Bacterial Agents (Antibiotics)IBA
01/2021
1ChromatinIBA
01/2021
1RNA (Ribonucleic Acid)IBA
01/2021
1Histone Deacetylase InhibitorsIBA
01/2020
1Chemokine CCL5IBA
12/2017
1Insulin-Like Growth Factor Binding Protein 3IBA
10/2017
1Biological ProductsIBA
01/2017
1PND 1186IBA
09/2015
1AntigensIBA
09/2015
1LigandsIBA
09/2015
1PLX 4720IBA
04/2015
1Cre recombinaseIBA
02/2012
1matriptaseIBA
01/2012
1Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA
07/2011
1Fluorescent Dyes (Fluorescent Probes)IBA
07/2011
1Leucine-Rich Repeat ProteinsIBA
06/2011
1TransducinIBA
06/2011
1Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA
06/2011
1CateninsIBA
06/2011
1TalinIBA
05/2011
1calpain inhibitorsIBA
05/2011
1erythromycin propionate-N-acetylcysteinateIBA
01/2011
1AgarIBA
10/2010
1Transforming Growth Factor beta (TGF-beta)IBA
08/2010
1CarcinogensIBA
08/2010
1GelsIBA
06/2010
1Mutant Proteins (Protein, Mutant)IBA
06/2010
1saracatinibIBA
02/2009
1anthraceneIBA
02/2009
1Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA
10/2008
1Actins (F Actin)IBA
09/2007
1Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
07/2007
1Glial Fibrillary Acidic ProteinIBA
07/2007
1Heparin (Liquaemin)FDA LinkGeneric
07/2007
1Chondroitin Sulfate ProteoglycansIBA
07/2007
1Phosphoric Diester Hydrolases (Phosphodiesterases)IBA
06/2007
1ColforsinIBA
06/2007
1Phosphodiesterase 3 InhibitorsIBA
06/2007
1Adenylyl Cyclases (Adenylyl Cyclase)IBA
06/2007
1Cyclic AMP (AMP, Cyclic)IBA
06/2007
1TensinsIBA
06/2007
1RolipramIBA
06/2007
1Phosphodiesterase 4 InhibitorsIBA
06/2007
1cilostamideIBA
06/2007
1Type 4 Cyclic Nucleotide PhosphodiesterasesIBA
06/2007
1Growth Factor ReceptorsIBA
05/2007
1Phospho-Specific AntibodiesIBA
12/2006
1PaxillinIBA
12/2006
1Tyrosine (L-Tyrosine)FDA Link
01/2006
1afimoxifene (hydroxytamoxifen)IBA
12/2004
1Irinotecan (Camptosar)FDA LinkGeneric
10/2004
1Oxaliplatin (Eloxatin)FDA LinkGeneric
10/2004
1Death Domain ReceptorsIBA
10/2004
1VinculinIBA
08/2002

Therapy/Procedure

5Therapeutics
01/2021 - 08/2010
1Immunotherapy
01/2021
1Drug Therapy (Chemotherapy)
10/2004